Skip to Main Content
Corporate

Quadruple Screen Test

General Information About the Test

The Quadruple Screen Test is an important pregnancy screening test performed using a blood sample taken from the expectant mother between the 16th and 20th weeks of pregnancy. It evaluates the risks of genetic anomalies in the baby, such as Down Syndrome (Trisomy 21), Trisomy 18, and Neural Tube Defects (spinal cord openings). It is a method with increased accuracy, achieved by adding the inhibin-A hormone to the triple screen test.

Test Process and Preparation

Administration of the quadruple screen test and evaluation of the results.

No, the quadruple screen test is not a diagnostic test; it is a "risk assessment" (screening) test. A high-risk result does not definitively mean the baby is affected; it merely indicates that an amniocentesis or fetal DNA test should be performed for a definitive diagnosis.

Four different values found in the mother's blood are examined: AFP (Alpha-fetoprotein), hCG, Estriol (uE3), and Inhibin-A. These values are combined with the mother's age, weight, and gestational week in a computer program to calculate the risk ratio.

The test is performed with a simple blood sample drawn from the mother's arm, and it does not require fasting or any special preparation.

The information on this page is for informational purposes only. The results of medical tests must be evaluated by specialist physicians.

You can find all the information regarding your treatment and hospital stay process in this section.

Maternity Services

Details

Patient Visits

Details

Your Hospital Stay

Details

Nursing Services

Details
E-Appointment
E-Consultation
Contact Us
App

Çakırtepe Hospital

Mobil Uygulama ★★★★★